Geron Corporation's (NASDAQ:GERN) Shift From Loss To Profit
Geron Corporation's (NASDAQ:GERN) Shift From Loss To Profit
With the business potentially at an important milestone, we thought we'd take a closer look at Geron Corporation's (NASDAQ:GERN) future prospects. Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The US$2.7b market-cap company posted a loss in its most recent financial year of US$184m and a latest trailing-twelve-month loss of US$220m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Geron's investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
考虑到Geron Corporation(NASDAQ:GERN)可能迎来重要里程碑,我们决定更加深入地探讨该公司的未来前景。Geron Corporation是一家晚期临床生物制药公司,专注于为骨髓造血恶性肿瘤开发和商业化治疗方案。这家市值27亿美元的公司在最近一个财年中亏损1340万美元,并在最新的过去十二个月中亏损2200万美元,导致亏损与盈亏平衡之间的差距更加扩大。因为通向盈利的道路是Geron投资者关心的话题,所以我们决定衡量市场情绪。在本文中,我们将谈到该公司的增长预期以及分析师预计何时实现盈利。
Geron is bordering on breakeven, according to the 5 American Biotechs analysts. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$111m in 2026. Therefore, the company is expected to breakeven roughly 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 66%, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.
据5家美国生物技术分析师表示,Geron的收支接近平衡。他们预计该公司将于2025年最终亏损,然后在2026年产生1110万美元的正利润。因此,该公司预计将在大约2年后实现盈亏平衡。以何种年度增长率才能于此日期实现盈亏平衡?使用最佳拟合线,我们计算出平均年增长率为66%,这表明分析师对其抱有高度信心。如果业务增长缓慢,则将在预期之后实现盈利。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240810/0-06d9ad3684a9fcab7084048be254f3d3-0-ae2c7b7a5e3e7548b8c810a49c25e235.png/big)
Given this is a high-level overview, we won't go into details of Geron's upcoming projects, however, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.
考虑到这只是一篇高层次的概述,我们不会详细介绍Geron即将推出的项目。然而,请记住,总体上来说,生物技术公司根据产品开发阶段有不规则的现金流期。这意味着高增长率并不罕见,特别是如果该公司目前处于投资期。
One thing we'd like to point out is that Geron has no debt on its balance sheet, which is rare for a loss-making biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
我们想指出的一件事是,Geron的资产负债表上没有债务,这在一家亏损的生物技术公司中是罕见的,而这类公司通常相对于股权有较高的债务水平。这意味着该公司一直在纯粹地依靠股权投资运营,没有债务负担。这一方面降低了投资这家亏损公司的风险。
Next Steps:
下一步:
There are too many aspects of Geron to cover in one brief article, but the key fundamentals for the company can all be found in one place – Geron's company page on Simply Wall St. We've also compiled a list of key factors you should further research:
Geron的方方面面无法在一篇简短的文章中涵盖,但该公司的关键基本面都可以在Simply Wall St的Geron公司页面上找到。我们还编制了一个关键要素列表,供您进一步研究:
- Valuation: What is Geron worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Geron is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Geron's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 估值:Geron今天值多少钱?未来的增长潜力是否已被市场因素考虑在内?我们免费的研究报告中的内在价值信息图形可以帮助您可视化地了解Geron当前是否被市场错定价了。
- 管理团队:经验丰富的管理团队能增强我们对业务的信心-请查看谁坐在Geron的董事会和CEO的背景情况。
- 其他高表现的股票:是否有其他表现更好的股票并具有经过验证的历史记录?查看这里的免费列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。